-
1
-
-
0020656868
-
Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years
-
Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85.
-
(1983)
Ann Intern Med
, vol.98
, pp. 76-85
-
-
Fauci, A.S.1
Haynes, B.F.2
Katz, P.3
-
2
-
-
66149168812
-
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibodyassociated vasculitis: A randomized controlled trial
-
De Groot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibodyassociated vasculitis: A randomized controlled trial. Ann Intern Med 2009; 150:670-680.
-
(2009)
Ann Intern Med
, vol.150
, pp. 670-680
-
-
De Groot, K.1
Harper, L.2
Jayne, D.R.W.3
-
3
-
-
0038122889
-
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies
-
Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
-
(2003)
N Engl J Med
, vol.349
, pp. 36-44
-
-
Jayne, D.1
Rasmussen, N.2
Andrassy, K.3
-
4
-
-
84856383829
-
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
-
Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64:542-548.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 542-548
-
-
Walsh, M.1
Flossmann, O.2
Berden, A.3
-
5
-
-
77955236779
-
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis
-
Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res 2010; 62:1166-1173.
-
(2010)
Arthritis Care Res
, vol.62
, pp. 1166-1173
-
-
Walsh, M.1
Merkel, P.A.2
Mahr, A.3
-
6
-
-
78649728808
-
Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial
-
Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA 2010; 304:2381-2388.
-
(2010)
JAMA
, vol.304
, pp. 2381-2388
-
-
Hiemstra, T.F.1
Walsh, M.2
Mahr, A.3
-
7
-
-
77749277070
-
Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement - A prospective, open-label pilot trial
-
Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement - A prospective, open-label pilot trial. Clin J Am Soc Nephrol 2010; 5:445-453.
-
(2010)
Clin J Am Soc Nephrol
, Issue.5
, pp. 445-453
-
-
Silva, F.1
Specks, U.2
Kalra, S.3
-
8
-
-
42949083859
-
Mycophenolatemofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement
-
Hu W, Liu C, Xie H, et al. Mycophenolatemofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008; 23:1307-1312.
-
(2008)
Nephrol Dial Transplant
, vol.23
, pp. 1307-1312
-
-
Hu, W.1
Liu, C.2
Xie, H.3
-
9
-
-
0037305174
-
15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: A six-month open-label trial to evaluate safety and efficacy
-
Birck R, Warnatz K, Lorenz HM, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: A six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003; 14:440-447.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 440-447
-
-
Birck, R.1
Warnatz, K.2
Lorenz, H.M.3
-
10
-
-
79952928275
-
Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: A meta-analysis
-
Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: A meta-analysis. Am J Kidney Dis 2011; 57:566-574.
-
(2011)
Am J Kidney Dis
, vol.57
, pp. 566-574
-
-
Walsh, M.1
Catapano, F.2
Szpirt, W.3
-
11
-
-
84874932394
-
Plasma exchange and glucocorticoid dosing in the treatment of antineutrophil cytoplasm antibody associated vasculitis (PEXIVAS): Protocol for a randomized controlled trial
-
Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of antineutrophil cytoplasm antibody associated vasculitis (PEXIVAS): Protocol for a randomized controlled trial. Trials 2013; 14:73.
-
(2013)
Trials
, Issue.14
, pp. 73
-
-
Walsh, M.1
Merkel, P.A.2
Peh, C.A.3
-
12
-
-
25444502877
-
Is PR3-ANCA formation initiated in wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production
-
Voswinkel J, Müller A, Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci 2005; 1051:12-19.
-
(2005)
Ann N Y Acad Sci
, vol.1051
, pp. 12-19
-
-
Voswinkel, J.1
Müller, A.2
Lamprecht, P.3
-
13
-
-
33745697938
-
B lymphocyte maturation in Wegener's granulomatosis: A comparative analysis of VH genes from endonasal lesions
-
Voswinkel J, Müller A, Kraemer JA, et al. B lymphocyte maturation in Wegener's granulomatosis: A comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65:859-864.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 859-864
-
-
Voswinkel, J.1
Müller, A.2
Kraemer, J.A.3
-
14
-
-
27844456394
-
BAFF is elevated in the serum of patients with Wegener's granulomatosis
-
Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in the serum of patients with Wegener's granulomatosis. J Autoimmun 2005; 25:298-302.
-
(2005)
J Autoimmun
, vol.25
, pp. 298-302
-
-
Krumbholz, M.1
Specks, U.2
Wick, M.3
-
15
-
-
0020051506
-
Suppression of human B lymphocyte function by cyclophosphamide
-
Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128:2453-2457.
-
(1982)
J Immunol
, vol.128
, pp. 2453-2457
-
-
Cupps, T.R.1
Edgar, L.C.2
Fauci, A.S.3
-
16
-
-
0036790387
-
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice
-
Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963.
-
(2002)
J Clin Invest
, vol.110
, pp. 955-963
-
-
Xiao, H.1
Heeringa, P.2
Hu, P.3
-
17
-
-
84855674846
-
Antiproteinase 3 antineutrophilcytoplasmautoantibodiesrecapitulatesystemic vasculitis in mice with a humanized immune system
-
Little MA, Al-Ani B, Ren S, et al. Antiproteinase 3 antineutrophilcytoplasmautoantibodiesrecapitulatesystemic vasculitis in mice with a humanized immune system. PLoS One 2012; 7:e28626.
-
(2012)
PLoS One
, Issue.7
-
-
Little, M.A.1
Al-Ani, B.2
Ren, S.3
-
18
-
-
77954651554
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis
-
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
-
(2010)
N Engl J Med
, Issue.363
, pp. 221-232
-
-
Stone, J.H.1
Merkel, P.A.2
Spiera, R.3
-
19
-
-
77954632414
-
Rituximab versus cyclophosphamide in ANCA-associatedrenalvasculitis
-
Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associatedrenalvasculitis. N Engl J Med 2010; 363:211-220.
-
(2010)
N Engl J Med
, Issue.363
, pp. 211-220
-
-
Jones, R.B.1
Tervaert, J.W.2
Hauser, T.3
-
20
-
-
84880882979
-
Efficacy of remission-induction regimens for ANCA-associated vasculitis
-
Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369:417-427.
-
(2013)
N Engl J Med
, Issue.369
, pp. 417-427
-
-
Specks, U.1
Merkel, P.A.2
Seo, P.3
-
21
-
-
84868087895
-
Rituximab for remission maintenance in relapsing ANCA-associated vasculitis
-
Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 2012; 64:3760- 3769.
-
(2012)
Arthritis Rheum
, Issue.64
, pp. 3760-3769
-
-
Smith, R.M.1
Jones, R.B.2
Guerry, M.J.3
-
22
-
-
77955767712
-
Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis
-
Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394-1400.
-
(2010)
Clin J Am Soc Nephrol
, Issue.5
, pp. 1394-1400
-
-
Rhee, E.P.1
Laliberte, K.A.2
Niles, J.L.3
-
23
-
-
84868012506
-
Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center
-
Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center. Arthritis Rheum 2012; 64:3770- 3778.
-
(2012)
Arthritis Rheum
, Issue.64
, pp. 3770-3778
-
-
Cartin-Ceba, R.1
Golbin, J.M.2
Keogh, K.A.3
-
24
-
-
84889645482
-
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
-
Epub ahead of print]
-
Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2013. [Epub ahead of print]
-
(2013)
Ann Rheum Dis
-
-
Wallace, D.J.1
Kalunian, K.2
Petri, M.A.3
-
25
-
-
84879502096
-
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
-
Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 2013; 52:1313-1322.
-
(2013)
Rheumatology (Oxford)
, Issue.52
, pp. 1313-1322
-
-
Wallace, D.J.1
Gordon, C.2
Strand, V.3
-
27
-
-
84863116877
-
Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy
-
Berden AE, Jones RB, Erasmus DD, et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am SocNephrol 2012; 23:313-321.
-
(2012)
J Am SocNephrol
, Issue.23
, pp. 313-321
-
-
Berden, A.E.1
Jones, R.B.2
Erasmus, D.D.3
-
28
-
-
50249107909
-
Long-term follow-up of relapsing/refractoryanti- neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H
-
Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/ refractoryanti- neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008; 67:1322-1327.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1322-1327
-
-
Walsh, M.1
Chaudhry, A.2
Jayne, D.3
-
29
-
-
67349223570
-
Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauciimmune vasculitis
-
Xing GQ, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauciimmune vasculitis. J Clin Immunol 2009; 29:282-291.
-
(2009)
J Clin Immunol
, vol.29
, pp. 282-291
-
-
Xing, G.Q.1
Chen, M.2
Liu, G.3
-
30
-
-
33847052568
-
Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies
-
Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170:52-64.
-
(2007)
Am J Pathol
, vol.170
, pp. 52-64
-
-
Xiao, H.1
Schreiber, A.2
Heeringa, P.3
-
31
-
-
84861981026
-
C5a and its receptors in human antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
-
Yuan J, Gou SJ, Huang J, et al. C5a and its receptors in human antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther 2012; 14:R140.
-
(2012)
Arthritis Res Ther
, Issue.14
-
-
Yuan, J.1
Gou, S.J.2
Huang, J.3
-
32
-
-
2642680076
-
Active Wegener's granulomatosis is associated with HLA-DRCD4T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10
-
Ludviksson BR, SnellerMC, Chua KS, et al. Active Wegener's granulomatosis is associated with HLA-DRCD4T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10. J Immunol 1998; 160:3602- 3609.
-
(1998)
J Immunol
, vol.160
, pp. 3602-3609
-
-
Ludviksson, B.R.1
Sneller, M.C.2
Chua, K.S.3
-
33
-
-
0036796830
-
Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitis: An open pilot study on 10 patients
-
Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitis: An open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126-1132.
-
(2002)
Rheumatology (Oxford)
, vol.41
, pp. 1126-1132
-
-
Bartolucci, P.1
Ramanoelina, J.2
Cohen, P.3
-
34
-
-
0035033807
-
Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety
-
Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44:1149-1154.
-
(2001)
Arthritis Rheum
, vol.44
, pp. 1149-1154
-
-
Stone, J.H.1
Uhlfelder, M.L.2
Hellmann, D.B.3
-
35
-
-
12544253745
-
Etanercept plus standard therapy for Wegener's granulomatosis
-
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
-
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
-
(2005)
N Engl J Med
, vol.352
, pp. 351-361
-
-
-
36
-
-
77957240329
-
Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement
-
Laurino S, Chaudhry A, Booth A, et al. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant 2010; 25:3307-3314.
-
(2010)
Nephrol Dial Transplant
, Issue.25
, pp. 3307-3314
-
-
Laurino, S.1
Chaudhry, A.2
Booth, A.3
-
37
-
-
1542288825
-
Prospective study of TNFalphablockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis
-
Booth A, Harper L, Hammad T, et al. Prospective study of TNFalphablockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am SocNephrol 2004; 15:717-721.
-
(2004)
J Am SocNephrol
, vol.15
, pp. 717-721
-
-
Booth, A.1
Harper, L.2
Hammad, T.3
-
38
-
-
0000752307
-
In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis
-
Kobold ACM, Wijk RTV, Franssen CFM, et al. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Rheumatol 1999; 17:433-440.
-
(1999)
Clin Exp Rheumatol
, vol.17
, pp. 433-440
-
-
Kobold, A.C.M.1
Wijk, R.T.V.2
Franssen, C.F.M.3
-
39
-
-
80053159298
-
Complete remission of myeloperoxidaseantineutrophilcytoplasmicantibody- Associatedcrescentglomerulonephritiscomplicatedwithrheumatoidarthritisusing a humanized antiinterleukin 6 receptor antibody
-
Sumida K, Ubara Y, Suwabe T, et al. Complete remission of myeloperoxidaseantineutrophilcytoplasmicantibody- Associatedcrescentglomerulonephritiscomplicatedwithrheumatoidarthritisusing a humanized antiinterleukin 6 receptor antibody. Rheumatology (Oxford) 2011; 50:1928-1930.
-
(2011)
Rheumatology (Oxford)
, vol.50
, pp. 1928-1930
-
-
Sumida, K.1
Ubara, Y.2
Suwabe, T.3
-
40
-
-
79551667105
-
Myeloperoxidase-specific plasma cell depletion by bortezomib protects from antineutrophil cytoplasmic autoantibodies- induced glomerulonephritis
-
Bontscho J, Schreiber A, Manz RA, et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from antineutrophil cytoplasmic autoantibodies- induced glomerulonephritis. J Am SocNephrol 2011; 22:336- 348.
-
(2011)
J Am SocNephrol
, Issue.22
, pp. 336-348
-
-
Bontscho, J.1
Schreiber, A.2
Manz, R.A.3
-
41
-
-
1542348997
-
Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18
-
Hewins P, Williams JM, Wakelam MJ, Savage CO. Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18. J Am SocNephrol 2004; 15:796-808.
-
(2004)
J Am SocNephrol
, vol.15
, pp. 796-808
-
-
Hewins, P.1
Williams, J.M.2
Wakelam, M.J.3
Savage, C.O.4
-
42
-
-
39749146417
-
Treatment of Churg-Strauss syndrome without poor-prognosis factors: Amulticenter, prospective, randomized, openlabel study of seventy-two patients
-
Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: Amulticenter, prospective, randomized, openlabel study of seventy-two patients. Arthritis Rheum 2008; 58:586-594.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 586-594
-
-
Ribi, C.1
Cohen, P.2
Pagnoux, C.3
-
43
-
-
45749109391
-
Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production
-
Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47:1104- 1105.
-
(2008)
Rheumatology (Oxford)
, vol.47
, pp. 1104-1105
-
-
Pepper, R.J.1
Fabre, M.A.2
Pavesio, C.3
-
44
-
-
80053215159
-
Rituximab for the treatment of Churg-Strauss syndrome with renal involvement
-
Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011; 26:2865-2871.
-
(2011)
Nephrol Dial Transplant
, Issue.26
, pp. 2865-2871
-
-
Cartin-Ceba, R.1
Keogh, K.A.2
Specks, U.3
-
45
-
-
77952737931
-
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
-
Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125:1336-1343.
-
(2010)
J Allergy Clin Immunol
, Issue.125
, pp. 1336-1343
-
-
Kim, S.1
Marigowda, G.2
Oren, E.3
-
46
-
-
80052509804
-
Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome
-
Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155:341- 343.
-
(2011)
Ann Intern Med
, Issue.155
, pp. 341-343
-
-
Moosig, F.1
Gross, W.L.2
Herrmann, K.3
-
47
-
-
77954591017
-
Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: A long-term observational study
-
Metzler C, Csernok E, Gross WL, Hellmich B. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: A long-term observational study. Clin Exp Rheumatol 2010; 28:24-30.
-
(2010)
Clin Exp Rheumatol
, Issue.28
, pp. 24-30
-
-
Metzler, C.1
Csernok, E.2
Gross, W.L.3
Hellmich, B.4
-
48
-
-
84864014453
-
Genetically Distinct Subsets within ANCA-associated Vasculitis
-
Lyons PA, Rayner TF, Trivedi S, et al. Genetically Distinct Subsets within ANCA-associated Vasculitis. N Engl J Med 2012; 367:214-223.
-
(2012)
N Engl J Med
, Issue.367
, pp. 214-223
-
-
Lyons, P.A.1
Rayner, T.F.2
Trivedi, S.3
-
49
-
-
84883258487
-
Clinical outcomes of remission induction therapy for severe ANCA-associated vasculitis
-
Miloslavsky E, Specks U, Merkel P, et al. Clinical outcomes of remission induction therapy for severe ANCA-associated vasculitis. Arthritis Rheum 2013; 65:2441-2449.
-
(2013)
Arthritis Rheum
, Issue.65
, pp. 2441-2449
-
-
Miloslavsky, E.1
Specks, U.2
Merkel, P.3
-
50
-
-
68549128699
-
Extracorporeal membrane oxygenation for the management of respiratory failure caused by diffuse alveolar hemorrhage
-
Guo Z, Li X, Jiang LY, Xu LF. Extracorporeal membrane oxygenation for the management of respiratory failure caused by diffuse alveolar hemorrhage. J Extra Corpor Technol 2009; 41:37-40
-
(2009)
J Extra Corpor Technol
, vol.41
, pp. 37-40
-
-
Guo, Z.1
Li, X.2
Jiang, L.Y.3
Xu, L.F.4
|